Article
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 2002
Crul M, de Klerk G J, Swart M, van't Veer L J, de Jong D, Boerrigter L, Palmer P A, Bol C J, Tan H, de Gast G C, Beijnen J H, Schellens J H M
Abstract excerpt
PURPOSE: To determine the maximum-tolerated dose, toxicities, and pharmacokinetics of R115777, a farnesyl transferase inhibitor, when administered continuously via the oral route. PATIENTS AND METHODS: Patients with advanced solid malignancies were treated with R115777 using an interpatient dose escalation scheme starting at 50 mg bid. Pharmacokinetics were assessed on days 1, 28, and 56. RESULTS: Twenty-eight...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.